The implantable insulin pump market size has grown strongly in recent years. It will grow from $3.88 billion in 2025 to $4.26 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of type 1 diabetes, limitations of multiple daily insulin injections, early development of implantable pump technology, growing awareness of intensive insulin therapy, hospital-based diabetes management practices.
The implantable insulin pump market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising adoption of automated insulin delivery systems, advancements in implantable medical device design, increasing demand for personalized diabetes care, expansion of home-based diabetes management, favorable reimbursement and regulatory support. Major trends in the forecast period include rising adoption of implantable insulin delivery systems, growing preference for closed-loop insulin pumps, improved glycemic control through continuous insulin infusion, increasing acceptance of long-term implantable diabetes devices, enhanced focus on patient convenience and therapy adherence.
The rise in diabetes incidence is increasingly supporting the expansion of the implantable insulin pump market going forward. Diabetes is a chronic condition in which the body struggles to regulate blood glucose levels due to insufficient insulin production or ineffective insulin utilization. The growing number of diabetes cases is linked to rising obesity rates, physical inactivity, unhealthy dietary habits, and aging populations. Implantable insulin pumps provide precise and continuous insulin delivery, helping stabilize blood glucose levels, reduce the frequency of injections, and improve overall diabetes management and patient quality of life. For example, in May 2024, according to Diabetes UK, a UK-based charity, more than 5.6 million people were living with diabetes in the UK, with 2022-23 figures showing an increase of 167,822 cases compared to the previous year. Consequently, the rising incidence of diabetes is reinforcing expansion within the implantable insulin pump market.
Leading companies in the implantable insulin pump market are increasingly forming strategic partnerships to develop high-concentration, thermostable insulin formulations for next-generation implantable pumps. For example, in May 2024, Arecor Therapeutics plc, a US-based biopharmaceutical company, partnered with Medtronic Diabetes, a US-based medical technology company, to develop a novel insulin formulation using Arecor’s Arestat technology platform. This formulation is designed for patients with limited options under conventional insulin delivery and aims to improve outcomes by reducing pump maintenance, enabling hepatic absorption, expanding clinical use, and lowering healthcare costs.
In June 2024, Arecor Therapeutics plc, a UK-based biotechnology company, partnered with Medtronic plc to develop a high-concentration, thermostable insulin for Medtronic’s advanced implantable insulin pump systems. This collaboration seeks to improve treatment options for diabetes patients requiring intensive insulin therapy. Medtronic plc is an Ireland-based manufacturer of implantable insulin pumps.
Major companies operating in the implantable insulin pump market are Sanofi S.A., Abbott Laboratories, Medtronic plc, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Air Liquide Healthcare Ltd., Diabeloop SA, Glooko Inc., ViCentra B.V., Bigfoot Biomedical Inc., Beta Bionics Inc., Senseonics Holdings Inc., INREDA DIABETIC B.V., TIDEPOOL Inc., Medtrum Technologies Inc., Sernova Corp., PhysioLogic Devices Inc., EOFLOW CO. LTD., CamDiab Ltd.
North America was the largest region in the implantable insulin pump market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable insulin pump market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable insulin pump market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable insulin pump market by increasing the cost of imported electronic components, sensors, and precision manufacturing equipment used in pump production. Closed-loop insulin pump systems and smart open-loop pumps are particularly impacted, with North America and Asia-Pacific regions facing higher device costs due to cross-border supply dependencies. These tariffs have contributed to elevated pricing and slower adoption in cost-sensitive markets. However, they have also encouraged local manufacturing, supply chain diversification, and innovation in cost-efficient implantable pump technologies.
The implantable insulin pump market research report is one of a series of new reports that provides implantable insulin pump market statistics, including implantable insulin pump industry global market size, regional shares, competitors with a implantable insulin pump market share, detailed implantable insulin pump market segments, market trends and opportunities, and any further data you may need to thrive in the implantable insulin pump industry. This implantable insulin pump market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An implantable insulin pump is a surgically placed device that delivers insulin directly into the peritoneal cavity, continuously adjusting doses according to the patient’s needs to help maintain stable blood sugar levels and reduce diabetes-related complications compared to daily injections.
The main types of implantable insulin pumps include closed-loop insulin pumps and open-loop insulin pumps. Closed-loop insulin pumps, also referred to as artificial pancreas systems, are advanced devices that automatically manage blood glucose levels in individuals with diabetes. These pumps are used for applications such as type 1 diabetes and type 2 diabetes and are utilized by end users including hospitals and homecare settings.
The implantable insulin pump market consists of sales of pump devices, delivery catheters, control systems, and insulin reservoirs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The implantable insulin pump market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising adoption of automated insulin delivery systems, advancements in implantable medical device design, increasing demand for personalized diabetes care, expansion of home-based diabetes management, favorable reimbursement and regulatory support. Major trends in the forecast period include rising adoption of implantable insulin delivery systems, growing preference for closed-loop insulin pumps, improved glycemic control through continuous insulin infusion, increasing acceptance of long-term implantable diabetes devices, enhanced focus on patient convenience and therapy adherence.
The rise in diabetes incidence is increasingly supporting the expansion of the implantable insulin pump market going forward. Diabetes is a chronic condition in which the body struggles to regulate blood glucose levels due to insufficient insulin production or ineffective insulin utilization. The growing number of diabetes cases is linked to rising obesity rates, physical inactivity, unhealthy dietary habits, and aging populations. Implantable insulin pumps provide precise and continuous insulin delivery, helping stabilize blood glucose levels, reduce the frequency of injections, and improve overall diabetes management and patient quality of life. For example, in May 2024, according to Diabetes UK, a UK-based charity, more than 5.6 million people were living with diabetes in the UK, with 2022-23 figures showing an increase of 167,822 cases compared to the previous year. Consequently, the rising incidence of diabetes is reinforcing expansion within the implantable insulin pump market.
Leading companies in the implantable insulin pump market are increasingly forming strategic partnerships to develop high-concentration, thermostable insulin formulations for next-generation implantable pumps. For example, in May 2024, Arecor Therapeutics plc, a US-based biopharmaceutical company, partnered with Medtronic Diabetes, a US-based medical technology company, to develop a novel insulin formulation using Arecor’s Arestat technology platform. This formulation is designed for patients with limited options under conventional insulin delivery and aims to improve outcomes by reducing pump maintenance, enabling hepatic absorption, expanding clinical use, and lowering healthcare costs.
In June 2024, Arecor Therapeutics plc, a UK-based biotechnology company, partnered with Medtronic plc to develop a high-concentration, thermostable insulin for Medtronic’s advanced implantable insulin pump systems. This collaboration seeks to improve treatment options for diabetes patients requiring intensive insulin therapy. Medtronic plc is an Ireland-based manufacturer of implantable insulin pumps.
Major companies operating in the implantable insulin pump market are Sanofi S.A., Abbott Laboratories, Medtronic plc, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Air Liquide Healthcare Ltd., Diabeloop SA, Glooko Inc., ViCentra B.V., Bigfoot Biomedical Inc., Beta Bionics Inc., Senseonics Holdings Inc., INREDA DIABETIC B.V., TIDEPOOL Inc., Medtrum Technologies Inc., Sernova Corp., PhysioLogic Devices Inc., EOFLOW CO. LTD., CamDiab Ltd.
North America was the largest region in the implantable insulin pump market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable insulin pump market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable insulin pump market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable insulin pump market by increasing the cost of imported electronic components, sensors, and precision manufacturing equipment used in pump production. Closed-loop insulin pump systems and smart open-loop pumps are particularly impacted, with North America and Asia-Pacific regions facing higher device costs due to cross-border supply dependencies. These tariffs have contributed to elevated pricing and slower adoption in cost-sensitive markets. However, they have also encouraged local manufacturing, supply chain diversification, and innovation in cost-efficient implantable pump technologies.
The implantable insulin pump market research report is one of a series of new reports that provides implantable insulin pump market statistics, including implantable insulin pump industry global market size, regional shares, competitors with a implantable insulin pump market share, detailed implantable insulin pump market segments, market trends and opportunities, and any further data you may need to thrive in the implantable insulin pump industry. This implantable insulin pump market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An implantable insulin pump is a surgically placed device that delivers insulin directly into the peritoneal cavity, continuously adjusting doses according to the patient’s needs to help maintain stable blood sugar levels and reduce diabetes-related complications compared to daily injections.
The main types of implantable insulin pumps include closed-loop insulin pumps and open-loop insulin pumps. Closed-loop insulin pumps, also referred to as artificial pancreas systems, are advanced devices that automatically manage blood glucose levels in individuals with diabetes. These pumps are used for applications such as type 1 diabetes and type 2 diabetes and are utilized by end users including hospitals and homecare settings.
The implantable insulin pump market consists of sales of pump devices, delivery catheters, control systems, and insulin reservoirs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Implantable Insulin Pump Market Characteristics
3. Implantable Insulin Pump Market Supply Chain Analysis
4. Global Implantable Insulin Pump Market Trends and Strategies
5. Implantable Insulin Pump Market Analysis of End Use Industries
7. Global Implantable Insulin Pump Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Implantable Insulin Pump Total Addressable Market (TAM) Analysis for the Market
9. Implantable Insulin Pump Market Segmentation
10. Implantable Insulin Pump Market Regional and Country Analysis
11. Asia-Pacific Implantable Insulin Pump Market
12. China Implantable Insulin Pump Market
13. India Implantable Insulin Pump Market
14. Japan Implantable Insulin Pump Market
15. Australia Implantable Insulin Pump Market
16. Indonesia Implantable Insulin Pump Market
17. South Korea Implantable Insulin Pump Market
18. Taiwan Implantable Insulin Pump Market
19. South East Asia Implantable Insulin Pump Market
20. Western Europe Implantable Insulin Pump Market
21. UK Implantable Insulin Pump Market
22. Germany Implantable Insulin Pump Market
23. France Implantable Insulin Pump Market
24. Italy Implantable Insulin Pump Market
25. Spain Implantable Insulin Pump Market
26. Eastern Europe Implantable Insulin Pump Market
27. Russia Implantable Insulin Pump Market
28. North America Implantable Insulin Pump Market
29. USA Implantable Insulin Pump Market
30. Canada Implantable Insulin Pump Market
31. South America Implantable Insulin Pump Market
32. Brazil Implantable Insulin Pump Market
33. Middle East Implantable Insulin Pump Market
34. Africa Implantable Insulin Pump Market
36. Implantable Insulin Pump Market Competitive Landscape and Company Profiles
37. Implantable Insulin Pump Market Other Major and Innovative Companies
40. Implantable Insulin Pump Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Implantable Insulin Pump Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses implantable insulin pump market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for implantable insulin pump? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable insulin pump market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Fully Implantable Insulin Pump; Semi-Implantable Insulin Pump2) By Application: Type 1 Diabetes; Type 2 Diabetes
3) By End-User: Hospitals; Diabetes Clinics; Home-Care
Subsegments:
1) By Fully Implantable Insulin Pump: Fully Automated Implantable Insulin Pump; Implantable Insulin Pump with Continuous Glucose Monitoring (CGM); Implantable Insulin Pump with Adaptive Insulin Delivery2) By Semi-Implantable Insulin Pump: Semi-Automated Semi-Implantable Insulin Pump; Basal-Bolus Semi-Implantable Insulin Pump; Patch-Assisted Semi-Implantable Insulin Pump; Remote-Controlled Semi-Implantable Insulin Pump
Companies Mentioned: Sanofi S.A.; Abbott Laboratories; Medtronic plc; Dexcom Inc.; Insulet Corporation; Tandem Diabetes Care Inc.; Ypsomed Holding AG; Air Liquide Healthcare Ltd.; Diabeloop SA; Glooko Inc.; ViCentra B.V.; Bigfoot Biomedical Inc.; Beta Bionics Inc.; Senseonics Holdings Inc.; INREDA DIABETIC B.V.; TIDEPOOL Inc.; Medtrum Technologies Inc.; Sernova Corp.; PhysioLogic Devices Inc.; EOFLOW CO. LTD.; CamDiab Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Implantable Insulin Pump market report include:- Sanofi S.A.
- Abbott Laboratories
- Medtronic plc
- Dexcom Inc.
- Insulet Corporation
- Tandem Diabetes Care Inc.
- Ypsomed Holding AG
- Air Liquide Healthcare Ltd.
- Diabeloop SA
- Glooko Inc.
- ViCentra B.V.
- Bigfoot Biomedical Inc.
- Beta Bionics Inc.
- Senseonics Holdings Inc.
- INREDA DIABETIC B.V.
- TIDEPOOL Inc.
- Medtrum Technologies Inc.
- Sernova Corp.
- PhysioLogic Devices Inc.
- EOFLOW CO. LTD.
- CamDiab Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.26 Billion |
| Forecasted Market Value ( USD | $ 6.09 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
